18F-氟化钠PET在骨转移中的价值综述
本文综述18F-氟化钠(18F-NaF)PET/CT在骨转移评估中的生物学基础与成像原理,并与其他成像方式比较。文章讨论其在多种恶性肿瘤骨转移中的临床应用、判读局限与伪影,并展望定量PET、人工智能与混合成像的应用前景。
要点
- 18F-NaF PET/CT因血清除快、骨摄取高,是评估成骨性骨转移最敏感的分子成像方法之一。
- 其临床角色随疾病特异性PET示踪剂与混合成像进步而演变,需结合其他成像综合判读。
- 判读需注意假阳性、假阴性、伪影、闪烁现象及辐射剂量与可及性等局限。
核心结论
- 18F-NaF PET/CT对成骨性骨转移检测敏感,但临床角色随疾病特异性PET示踪剂和混合成像发展而演变。
- 综述强调现有证据支持其用于骨转移成像评估,并讨论其不断演变的作用。
研究设计与样本
- 本文为综述,系统概述18F-NaF PET/CT的生物学基础与成像原理,并与其他成像方式比较。
主要发现
- 18F-NaF因血清除快、骨摄取高,可识别与转移相关的骨重建增加区域。
- 综述比较了传统骨显像、SPECT/CT、CT、全身MRI及其他PET/CT示踪剂,并列出各自优缺点。
- 综述讨论了假阳性、假阴性、伪影、闪烁现象、成本与可及性有限及辐射剂量等局限。
- 综述提及定量PET、人工智能与混合成像是有望改善诊断性能与临床效用的工具。
临床怎么用
- 在成骨性骨转移评估中,可将18F-NaF PET/CT作为敏感分子成像选项之一。
- 判读时应结合病史与其他成像,注意假阳性、假阴性、伪影及闪烁现象的影响。
- 临床选用需权衡成本、可及性与辐射剂量,并关注定量PET与人工智能等新进展。
局限性
- 综述指出18F-NaF PET/CT存在假阳性与假阴性、伪影及闪烁现象等判读局限。
- 成本与可及性有限及辐射剂量考虑是其临床应用的限制因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bone metastases are a major cause of morbidity in patients with advanced cancer, making accurate detection essential for staging, treatment planning, and response assessment. Among molecular imaging techniques, 18F-sodium fluoride (18F-NaF) PET/CT is one of the most sensitive modalities for evaluating osteoblastic skeletal metastases because of its rapid blood clearance and high bone uptake identifying areas of increased bone remodeling associated with metastatic disease. Despite its excellent diagnostic performance, the clinical role of 18F-NaF PET/CT has evolved with the emergence of disease-specific PET radiotracers and advances in hybrid imaging. This review provides a comprehensive overview of the biological basis and imaging principles of 18F-NaF PET/CT, followed by comparison with other imaging modalities, including conventional bone scintigraphy, SPECT/CT, CT, whole-body MRI and other PET/CT tracers, highlighting the advantages and limitations of each modality. Clinical applications of 18F-NaF PET/CT in bone metastatic disease is discussed across malignancies. Limitations and pitfalls relevant to interpretation and clinical use of 18F-NaF PET/CT are reviewed, including false-positive and false-negative findings, artifacts, the flare phenomenon, cost and limited availability, and radiation dose considerations. Finally, advances in quantitative PET imaging, artificial intelligence, and hybrid imaging are discussed as promising tools to improve the diagnostic performance and clinical utility of 18F-NaF PET/CT. This review highlights the current evidence supporting the use of 18F-NaF PET/CT and discusses its evolving role in the imaging evaluation of bone metastases.
引用
- Torricelli C, Nogueira-Lima E, Etchebehere E, et al. The value of 18F-fluoride PET in bone metastases: an overview. Semin Nucl Med. 2026. PMID: 42754475. doi:10.1053/j.semnuclmed.2026.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。